clinical trial · NCT04317885
A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects
Shanghai Tongji Hospital, Tongji University School of Medicine·phase1·completed·n = 25
Non-Hodgkin's B-cell LymphomaPrizloncabtagene Autoleucel
brief summary
The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of C-CAR039 in treatment of relapsed or refractory NHL patients
started
Nov 5, 2019
primary completion
Jun 30, 2023
completion
Dec 30, 2023
last updated
May 23, 2025
detailed description
This study plans to enroll 25 patients to assess the safety and efficacy of C-CAR039. Subjects who meet the eligibility criteria will receive a single dose of C-CAR039 injection.
The study will include the following sequential phases: Screening, Apheresis and C-CAR039 manufacturing, Bridging (if needed), Baseline, lymphodepletion, C-CAR039 infusion, and Follow-up Visit.
official title
A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in Relapsed or Refractory NHL Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol